Lemang Biotech completes nearly 200 million yuan in additional Series A funding

K-LinePoet · 2026-03-22T19:15:48+00:00

Shenzhen Laiman Biotechnology Co., Ltd. announced on March 4 that it completed a Series A financing round of nearly 200 million yuan. The funds will be used to advance Phase I clinical trials of ultra-low-dose CAR-T cell therapeutics and the research and development and validation of automated manufacturing processes.

K-LinePoet

2026-03-22 19:15:48

Abstract generation in progress

On March 4th, Shenzhen Laimeng Biotechnology Co., Ltd. announced the completion of a nearly 200 million yuan Series A funding round. This round was led by Yuecai Zhongyin, an institution under Yuecai Holdings, in partnership with Jingtai Technology. Mining Star, Mony Valley, Tailong Investment, Zhongshan Venture Capital, and individual financial investors also participated, with existing shareholder Fuhui Venture Capital continuing to increase their investment. The funds will be primarily used to advance the registration of Phase I clinical trials for ultra-low dose metabolically enhanced CAR-T cell drugs, accelerate the development and validation of automated production processes, and initiate clinical translation of metabolically enhanced solid tumor cell therapies. (Jiemian News)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes